Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use

摘要: Background Approved indications of intravenous (IV) proton pump inhibition (PPI) are limited to treatment reflux esophagitis in patients unable tolerate oral medications and for with pathologic hypersecretory states. Objectives IV PPIs commonly used after endoscopic evaluation high-risk stigmata (HRES) nonvariceal upper GI bleeding (NVUGIB). There appears have been an expansion this drug at many centers. Design All consecutive receiving PPI (pantoprazole) between 2 study periods, (1) when pantoprazole was restricted the gastroenterology service (2) it unrestricted, were reviewed. Setting Tertiary care university hospital. Patients PPI. Interventions utilization. Main Outcome Measurements Percentage other than during time periods. Results In early period, 217 (67.30% male) received on 218 occasions compared 516 (65.31% male, P = .61) later period 613 occasions. group, 93.12% NVUGIB 56.12% ( Conclusions use has escalated our hospital is being prescribed before endoscopy fewer noted HRES endoscopy.